Enable job alerts via email!
A prominent NHS healthcare provider in Camden Town is seeking a Clinical Trial professional. This role involves overseeing the setup of clinical trials, including site selection and regulatory approvals. Ideal candidates should possess strong communication and negotiation skills and ideally have experience in oncology and haematology. Full training will be provided, and the environment is fast-paced and dynamic.
An exciting opportunity has arisen for a dynamic and driven Clinical Trial professional with set up and regulatory experience.
Working in a busy Cancer Clinical Trials Unit you will be the main contact for the set-up of clinical trials from Site Selection Visit, through budget and contract negotiation to regulatory approvals and site initiation.
You will be an integral part of the team, demonstrating outstanding communication and negotiation skills, motivated by challenging timelines and thriving in a fast paced environment. Full training will be provided but an understanding of oncology and haematology protocols will be a definite advantage.
University College London Hospitals NHS Foundation Trust (UCLH) is one of the most complex NHS trusts in the UK, serving a large and diverse population. We provide academically led acute and specialist services, to people from the local area, from throughout the United Kingdom and overseas. Our vision is to deliver top-quality patient care, excellent education, and world-class research.
We provide first-class acute and specialist services across eight sites:
We are dedicated to the diagnosis and treatment of many complex illnesses. UCLH specialises in women's health and the treatment of cancer, infection, neurological, gastrointestinal and oral disease. It has world class support services including critical care, imaging, nuclear medicine and pathology. We are committed to sustainability and have pledged to become a carbon net zero health service, embedding sustainable practice throughout UCLH. We have set an ambitious target of net zero for our direct emissions by 2031 and indirect emissions by 2040.